Skip to main content

Advertisement

Table 1 Baseline Characteristics

From: DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Docetaxel/Oxaliplatin (n = 44)
Patient Characteristics Number of Patients Percent
Sex
 Male 29 65.9
 Female 15 34.1
Age (years)
 Median (and range) 66.5 38–76
Karnofsky performance status score (n = 43)
 100 % 9 20.9
 90 % 21 48.8
 80 % 13 30.2
Prior surgery
 No 26 59
 Curative Intention 9 20.5
 Palliative 9 20.5
Prior radiotherapy   
 Yes 3 6.8
 No 41 93.2
Location of the primary
 Head 26 59.1
 Body 10 22.7
 Tail 8 18.2
Disease extension
 Locally advanced 8 18.2
 Metastatic 36 81.8
Metastatic sitesa   
 Liver 30 68.1
 Lymphnodes 10 22.7
 Lung 7 15.9
 Bone 2 4.5
Median duration of first line therapy (mts) 4.5 95 % CI 2.1–7.25
  1. amultiple presentations included; 95 % CI confidence interval